Sugi Predict

Sugi Predict / Compounds / SCHEMBL310302

SCHEMBL310302

SCHEMBL310302

COC(=O)[C@@H]1CCC(c2ccc(OCc3ccccc3F)cc2)=N1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 3/20 0.49
▸ KCNH2 Q12809 6/20 0.48
▸ PARP15 Q460N3 2/20 0.46
▸ PARP10 Q53GL7 2/20 0.46
▸ PARP14 Q460N5 1/20 0.46
▸ SCN3A Q9NY46 9/20 0.45
▸ SCN9A Q15858 2/20 0.45
▸ SCN1A P35498 1/20 0.45
▸ SCN4A P35499 1/20 0.45
▸ SCN7A Q01118 1/20 0.45
▸ SCN5A Q14524 1/20 0.45
▸ SCN2A Q99250 1/20 0.45
▸ SCN8A Q9UQD0 1/20 0.45
▸ SCN10A Q9Y5Y9 1/20 0.45
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2B6 P20813 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22546709 1.00 MAOB (0.49) MAOBKCNH2PARP15PARP10PARP14
SCHEMBL29385120 1.00 MAOB (0.49) MAOBKCNH2PARP15PARP10PARP14
SCHEMBL12079894 0.90 MAOB (0.47) MAOBKCNH2PARP15PARP10PARP14
SCHEMBL13320301 0.89 MAOB (0.54) MAOBKCNH2PARP15PARP10PARP14
SCHEMBL22534101 0.88 MAOB (0.49) MAOBKCNH2PARP15PARP10PARP14
SCHEMBL2712980 0.88 MAOB (0.49) MAOBKCNH2PARP15PARP10PARP14
SCHEMBL12973299 0.88 MAOB (0.47) MAOBKCNH2PARP15PARP10PARP14
SCHEMBL12973331 0.88 SCN3A (0.50) MAOBKCNH2PARP15PARP10PARP14
SCHEMBL22534112 0.87 SCN3A (0.54) MAOBKCNH2PARP15PARP10PARP14
SCHEMBL22534110 0.87 SCN3A (0.54) MAOBKCNH2PARP15PARP10PARP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220177426-A1 PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES BIOGEN MA INC. 2022-06-09 — — US disclosed
CN-114026066-A Process for preparing alpha-carboxamide pyrrolidine derivatives 生物基因麻省公司 2022-02-08 — — CN disclosed
WO-2020210485-A1 PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES BIOGEN MA INC. (US) 2020-10-15 — — WO disclosed
US-8153623-B2 Compounds Convergence Pharmaceuticals Limited (GB) 2012-04-10 — — US disclosed
US-8153623-B2 Compounds Convergence Pharmaceuticals Limited (GB) 2012-04-10 — — US disclosed
US-8153623-B2 Compounds Convergence Pharmaceuticals Limited (GB) 2012-04-10 — — US disclosed
US-8153681-B2 Method of treating epilepsy by administering 5-(4{[(2-fluorophenyl)methyl]oxy}phenyl)prolinamide Convergence Pharmaceuticals Limited (GB) 2012-04-10 — — US disclosed
US-8153681-B2 Method of treating epilepsy by administering 5-(4{[(2-fluorophenyl)methyl]oxy}phenyl)prolinamide Convergence Pharmaceuticals Limited (GB) 2012-04-10 — — US disclosed
US-8143306-B2 Methods of treating bipolar disorders Convergence Pharmaceuticals Limited (GB) 2012-03-27 — — US disclosed
US-8143306-B2 Methods of treating bipolar disorders Convergence Pharmaceuticals Limited (GB) 2012-03-27 — — US disclosed
US-20080293753-A1 Novel Compounds Convergence Pharmaceuticals Limited (GB) 2008-11-27 — — US disclosed
US-20080280969-A1 Novel Compounds GLAXO GROUP LIMITED 2008-11-13 — — US disclosed
WO-2008122546-A1 PROLINAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS GLAXO GROUP LIMITED (GB) 2008-10-16 — — WO disclosed
WO-2008090116-A1 NOVEL PHARMACEUTICAL COMPOSITIONS GLAXO GROUP LIMITED (GB) 2008-07-31 — — WO disclosed
WO-2008090114-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5- (5-TRIFLUOROMETHYL-TETRAZOL-I-YL-BENZYL) - (2S-PHENYL-PIPERIDIN-3S-YL-) GLAXO GROUP LIMITED (GB) 2008-07-31 — — WO disclosed
WO-2008090117-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 3, 5-DIAMIN0-6- (2, 3-DICHL0PHENYL) -L, 2, 4-TRIAZINE OR R (-) -2, 4-DIAMINO-5- (2, 3-DICHLOROPHENYL) -6-FLUOROMETHYL PYRIMIDINE AND AN NK1 GLAXO GROUP LIMITED (GB) 2008-07-31 — — WO disclosed
WO-2008090115-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED (GB) 2008-07-31 — — WO disclosed
WO-2007042239-A1 PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS GLAXO GROUP LIMITED (GB) 2007-04-19 — — WO disclosed
WO-2007042240-A1 QUATERNARY ALPHA-AMINOCARBOXAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS GLAXO GROUP LIMITED (GB) 2007-04-19 — — WO disclosed
WO-2007042250-A1 PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS GLAXO GROUP LIMITED (GB) 2007-04-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220177426-A1 PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES CPS1, PCCA, ALDH18A1 MAOB 114/4885KCNH2 774/4885PARP15 56/4885
US-20080280969-A1 Novel Compounds CYP11B2, CYP46A1, SLC10A1 MAOB 1719/4885KCNH2 1998/4885PARP15 1248/4885
US-20080293753-A1 Novel Compounds CACNA1E, CACNA1A, SCN1B MAOB 2215/4885KCNH2 15/4885PARP15 1340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.